6月22日，Moderna盘中下跌5.34%，报62.055美元/股，成交额8528.09万美元。此前该股在六个交易日内累计上涨39%，创下自去年9月以来最高水平。
消息面上，Leerink Partners将Moderna目标价从21美元上调至24美元，但维持跑输大盘评级。该目标价远低于当前股价，也明显低于分析师一致目标价47.05美元，反映出部分机构对公司近期涨幅的谨慎态度。此前公司mRNA流感疫苗获FDA顾问委员会全票推荐、德国产能扩张计划等多重利好已被充分消化，短期获利回吐压力显现。FDA最终审批决定预计8月初做出，在此之前市场可能进入消息真空期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.